Your browser doesn't support javascript.
loading
Adaptive radiosurgery based on two simultaneous dose prescriptions in the management of large renal cell carcinoma brain metastases in critical areas: Towards customization.
Sinclair, Georges; Stenman, M; Benmakhlouf, H; Johnstone, P; Wersäll, P; Lindskog, M; Hatiboglu, M A; Harmenberg, U.
Afiliação
  • Sinclair G; Departments of Neurosurgery, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.
  • Stenman M; Department of Neurosurgery, Bezmialem Vakif University Medical School, Istanbul, Turkey.
  • Benmakhlouf H; Department of Oncology, Royal Berkshire NHS Foundation Trust, Reading, United Kingdom.
  • Johnstone P; Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden.
  • Wersäll P; Departments of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.
  • Lindskog M; Department of Oncology, Royal Berkshire NHS Foundation Trust, Reading, United Kingdom.
  • Hatiboglu MA; Department of Oncology-Pathology, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.
  • Harmenberg U; Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Surg Neurol Int ; 11: 21, 2020.
Article em En | MEDLINE | ID: mdl-32123609
BACKGROUND: The long-term benefits of local therapy in metastatic renal cell carcinoma (mRCC) have been widely documented. In this context, single fraction gamma knife radiosurgery (SF-GKRS) is routinely used in the management of brain metastases. However, SF-GKRS is not always feasible due to volumetric and regional constraints. We intend to illustrate how a dose-volume adaptive hypofractionated GKRS technique based on two concurrent dose prescriptions termed rapid rescue radiosurgery (RRR) can be utilized in this particular scenario. CASE DESCRIPTION: A 56-year-old man presented with left-sided hemiparesis; the imaging showed a 13.1 cc brain metastasis in the right central sulcus (Met 1). Further investigation confirmed the histology to be a metastatic clear cell RCC. Met 1 was treated with upfront RRR. Follow-up magnetic resonance imaging (MRI) at 10 months showed further volume regression of Met 1; however, concurrently, a new 17.3 cc lesion was reported in the boundaries of the left frontotemporal region (Met 2) as well as a small metastasis (<1 cc) in the left temporal lobe (Met 3). Met 2 and Met 3 underwent RRR and SF-GKRS, respectively. RESULTS: Gradual and sustained tumor ablation of Met 1 and Met 2 was demonstrated on a 20 months long follow- up. The patient succumbed to extracranial disease 21 months after the treatment of Met 1 without evidence of neurological impairment post-RRR. CONCLUSION: Despite poor prognosis and precluding clinical factors (failing systemic treatment, eloquent location, and radioresistant histology), RRR provided optimal tumor ablation and salvage of neurofunction with limited toxicity throughout follow-up.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Surg Neurol Int Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Suécia

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Surg Neurol Int Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Suécia